The 2022 American Society of Hematology (ASH) Annual Meeting and Exposition was held from December 10 to 13 in New Orleans, Louisiana.
In this podcast, Christopher Flowers, MD, FASCO, discusses research presented at the meeting, including new treatments for non-Hodgkin lymphoma and new models for predicting which patients may be at risk for early disease progression.
Findings from the phase 3 TRIANGLE clinical trial, which was comparing the standard treatment for people with mantle cell lymphoma to 2 experimental treatment regimens that added the targeted therapy drug ibrutinib (Imbruvica) to chemotherapy either with or without autologous stem cell transplant followed by maintenance therapy with ibrutinib. [2:30]
Results from 2 studies evaluating the effectiveness of 2 different models designed to predict which patients may be at risk for early progression of their disease:
The FLIPI24 model used age, hemoglobin levels, white blood cell count, lactate dehydrogenase levels, and beta-2-microglobulin levels to predict which patients with follicular lymphoma may be at risk for early disease progression. [5:00]
An update on a type of immunotherapy discussed at the meeting called bispecific antibodies, which bring T cells into the tumor to attack the lymphoma cells. [7:11]
Dr. Flowers is the Chair of the Department of Lymphoma/Myeloma at The University of Texas MD Anderson Cancer Center and was appointed Division Head ad interim of Cancer Medicine in August 2020. Dr. Flowers is also the 2023 Cancer.Net Associate Editor for Lymphoma.
Disclosure information for Dr. Flowers can be found in his biography linked to above.
Was this podcast useful? Please subscribe, rate, and review Cancer.Net Podcasts wherever you listen to podcasts. This prerecorded podcast can be listened to online or downloaded to your computer. A transcript is also available. For more information, visit the Cancer.Net podcast page.
Cancer.Net podcasts are edited for length and content.